Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double Blind, Double Dummy, Randomized, Placebo-controlled, 5 Period Cross-over Study To Examine The Effect Of Pf-06273340 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls

Next Previous
Trial Profile

A Double Blind, Double Dummy, Randomized, Placebo-controlled, 5 Period Cross-over Study To Examine The Effect Of Pf-06273340 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PF 6273340 (Primary) ; Ibuprofen; Pregabalin
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 27 Nov 2017 Primary endpoint (Electrical pain tolerance threshold (400mg and 50 mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology
  • 27 Nov 2017 Primary endpoint (Pressure pain tolerance threshold (400mg and 50 mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology
  • 27 Nov 2017 Primary endpoint (Ultra-violet light sensitized pain detection threshold (50mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top